NPS Files Gattex NDA in SBS; Commercial Plan 'Set in Motion'

NPS Pharmaceuticals Inc. completed its new drug application (NDA) submission for Gattex (teduglutide) in short bowel syndrome (SBS), seeking a priority six-month review that could see the orphan drug on the market in the first half of next year.